Fully human monoclonal antibody directed to proteolytic cleavage site in Severe Acute Respiratory Syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model

Tohru Miyoshi-Akiyama, Isao Ishida, Masaya Fukushi, Keina Yamaguchi, Yusuke Matsuoka, Takashi Ishihara, Masayoshi Tsukahara, Seisuke Hatakeyama, Norikazu Itoh, Aki Morisawa, Yoshiyuki Yoshinaka, Naoki Yamamoto, Zhang Lianfeng, Qin Chuan, Teruo Kirikae, Takehiko Sasazuki

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background. There is still no effective method to prevent or treat severe acute respiratory syndrome (SARS), which is caused by SARS coronavirus (CoV). In the present study, we evaluated the efficacy of a fully human monoclonal antibody capable of neutralizing SARS-CoV in vitro in a Rhesus macaque model of SARS. Methods. The antibody 5H10 was obtained by vaccination of KM mice bearing human immunoglobulin genes with Escherichia coli-producing recombinant peptide containing the dominant epitope of the viral spike protein found in convalescent serum samples from patients with SARS. Results. 5H10, which recognized the same epitope that is also a cleavage site critical for the entry of SARS-CoV into host cells, inhibited propagation of the virus and pathological changes found in Rhesus macaques infected with the virus through the nasal route. In addition, we analyzed the mode of action of 5H10, and the results suggested that 5H10 inhibited fusion between the virus envelope and host cell membrane. 5H10 has potential for use in prevention and treatment of SARS if it reemerges. Conclusions. This study represents a platform to produce fully human antibodies against emerging infectious diseases in a timely and safe manner.

Original languageEnglish
Pages (from-to)1574-1581
Number of pages8
JournalJournal of Infectious Diseases
Volume203
Issue number11
DOIs
Publication statusPublished - Jun 1 2011
Externally publishedYes

Fingerprint

Severe Acute Respiratory Syndrome
Macaca mulatta
Monoclonal Antibodies
Viruses
Coronavirus
Epitopes
Emerging Communicable Diseases
Immunoglobulin Genes
Antibodies
Viral Proteins
S protein, severe acute respiratory syndrome coronavirus
Nose
Vaccination
Cell Membrane
Escherichia coli
Peptides
Serum

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Fully human monoclonal antibody directed to proteolytic cleavage site in Severe Acute Respiratory Syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. / Miyoshi-Akiyama, Tohru; Ishida, Isao; Fukushi, Masaya; Yamaguchi, Keina; Matsuoka, Yusuke; Ishihara, Takashi; Tsukahara, Masayoshi; Hatakeyama, Seisuke; Itoh, Norikazu; Morisawa, Aki; Yoshinaka, Yoshiyuki; Yamamoto, Naoki; Lianfeng, Zhang; Chuan, Qin; Kirikae, Teruo; Sasazuki, Takehiko.

In: Journal of Infectious Diseases, Vol. 203, No. 11, 01.06.2011, p. 1574-1581.

Research output: Contribution to journalArticle

Miyoshi-Akiyama, T, Ishida, I, Fukushi, M, Yamaguchi, K, Matsuoka, Y, Ishihara, T, Tsukahara, M, Hatakeyama, S, Itoh, N, Morisawa, A, Yoshinaka, Y, Yamamoto, N, Lianfeng, Z, Chuan, Q, Kirikae, T & Sasazuki, T 2011, 'Fully human monoclonal antibody directed to proteolytic cleavage site in Severe Acute Respiratory Syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model', Journal of Infectious Diseases, vol. 203, no. 11, pp. 1574-1581. https://doi.org/10.1093/infdis/jir084
Miyoshi-Akiyama, Tohru ; Ishida, Isao ; Fukushi, Masaya ; Yamaguchi, Keina ; Matsuoka, Yusuke ; Ishihara, Takashi ; Tsukahara, Masayoshi ; Hatakeyama, Seisuke ; Itoh, Norikazu ; Morisawa, Aki ; Yoshinaka, Yoshiyuki ; Yamamoto, Naoki ; Lianfeng, Zhang ; Chuan, Qin ; Kirikae, Teruo ; Sasazuki, Takehiko. / Fully human monoclonal antibody directed to proteolytic cleavage site in Severe Acute Respiratory Syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. In: Journal of Infectious Diseases. 2011 ; Vol. 203, No. 11. pp. 1574-1581.
@article{551f548fbf73479a90f8040a443b74c2,
title = "Fully human monoclonal antibody directed to proteolytic cleavage site in Severe Acute Respiratory Syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model",
abstract = "Background. There is still no effective method to prevent or treat severe acute respiratory syndrome (SARS), which is caused by SARS coronavirus (CoV). In the present study, we evaluated the efficacy of a fully human monoclonal antibody capable of neutralizing SARS-CoV in vitro in a Rhesus macaque model of SARS. Methods. The antibody 5H10 was obtained by vaccination of KM mice bearing human immunoglobulin genes with Escherichia coli-producing recombinant peptide containing the dominant epitope of the viral spike protein found in convalescent serum samples from patients with SARS. Results. 5H10, which recognized the same epitope that is also a cleavage site critical for the entry of SARS-CoV into host cells, inhibited propagation of the virus and pathological changes found in Rhesus macaques infected with the virus through the nasal route. In addition, we analyzed the mode of action of 5H10, and the results suggested that 5H10 inhibited fusion between the virus envelope and host cell membrane. 5H10 has potential for use in prevention and treatment of SARS if it reemerges. Conclusions. This study represents a platform to produce fully human antibodies against emerging infectious diseases in a timely and safe manner.",
author = "Tohru Miyoshi-Akiyama and Isao Ishida and Masaya Fukushi and Keina Yamaguchi and Yusuke Matsuoka and Takashi Ishihara and Masayoshi Tsukahara and Seisuke Hatakeyama and Norikazu Itoh and Aki Morisawa and Yoshiyuki Yoshinaka and Naoki Yamamoto and Zhang Lianfeng and Qin Chuan and Teruo Kirikae and Takehiko Sasazuki",
year = "2011",
month = "6",
day = "1",
doi = "10.1093/infdis/jir084",
language = "English",
volume = "203",
pages = "1574--1581",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Fully human monoclonal antibody directed to proteolytic cleavage site in Severe Acute Respiratory Syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model

AU - Miyoshi-Akiyama, Tohru

AU - Ishida, Isao

AU - Fukushi, Masaya

AU - Yamaguchi, Keina

AU - Matsuoka, Yusuke

AU - Ishihara, Takashi

AU - Tsukahara, Masayoshi

AU - Hatakeyama, Seisuke

AU - Itoh, Norikazu

AU - Morisawa, Aki

AU - Yoshinaka, Yoshiyuki

AU - Yamamoto, Naoki

AU - Lianfeng, Zhang

AU - Chuan, Qin

AU - Kirikae, Teruo

AU - Sasazuki, Takehiko

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background. There is still no effective method to prevent or treat severe acute respiratory syndrome (SARS), which is caused by SARS coronavirus (CoV). In the present study, we evaluated the efficacy of a fully human monoclonal antibody capable of neutralizing SARS-CoV in vitro in a Rhesus macaque model of SARS. Methods. The antibody 5H10 was obtained by vaccination of KM mice bearing human immunoglobulin genes with Escherichia coli-producing recombinant peptide containing the dominant epitope of the viral spike protein found in convalescent serum samples from patients with SARS. Results. 5H10, which recognized the same epitope that is also a cleavage site critical for the entry of SARS-CoV into host cells, inhibited propagation of the virus and pathological changes found in Rhesus macaques infected with the virus through the nasal route. In addition, we analyzed the mode of action of 5H10, and the results suggested that 5H10 inhibited fusion between the virus envelope and host cell membrane. 5H10 has potential for use in prevention and treatment of SARS if it reemerges. Conclusions. This study represents a platform to produce fully human antibodies against emerging infectious diseases in a timely and safe manner.

AB - Background. There is still no effective method to prevent or treat severe acute respiratory syndrome (SARS), which is caused by SARS coronavirus (CoV). In the present study, we evaluated the efficacy of a fully human monoclonal antibody capable of neutralizing SARS-CoV in vitro in a Rhesus macaque model of SARS. Methods. The antibody 5H10 was obtained by vaccination of KM mice bearing human immunoglobulin genes with Escherichia coli-producing recombinant peptide containing the dominant epitope of the viral spike protein found in convalescent serum samples from patients with SARS. Results. 5H10, which recognized the same epitope that is also a cleavage site critical for the entry of SARS-CoV into host cells, inhibited propagation of the virus and pathological changes found in Rhesus macaques infected with the virus through the nasal route. In addition, we analyzed the mode of action of 5H10, and the results suggested that 5H10 inhibited fusion between the virus envelope and host cell membrane. 5H10 has potential for use in prevention and treatment of SARS if it reemerges. Conclusions. This study represents a platform to produce fully human antibodies against emerging infectious diseases in a timely and safe manner.

UR - http://www.scopus.com/inward/record.url?scp=79956227227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956227227&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir084

DO - 10.1093/infdis/jir084

M3 - Article

C2 - 21592986

AN - SCOPUS:79956227227

VL - 203

SP - 1574

EP - 1581

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 11

ER -